Bio-Rad Laboratories (BIO) Current Deferred Revenue (2010 - 2022)

Bio-Rad Laboratories (BIO) has 13 years of Current Deferred Revenue data on file, last reported at $71.9 million in Q4 2022.

• On a quarterly basis, Current Deferred Revenue rose 41.39% year-over-year to $71.9 million in Q4 2022; TTM through Dec 2022 was $71.9 million, a 41.39% increase from a year earlier, with the FY2022 full-year figure at $71.9 million, up 41.39% from the prior year.
• Current Deferred Revenue for Q4 2022 stood at $71.9 million, up from $50.9 million in the prior quarter.
• Over the last five years, Current Deferred Revenue for BIO reached as high as $71.9 million in Q4 2022 and fell as low as $26.9 million in Q4 2018.
• Historically, Current Deferred Revenue has averaged $44.4 million across 5 years, with a median of $42.5 million in 2020.
• Across the five-year window, Current Deferred Revenue decreased 26.6% in 2018 and soared 41.39% in 2022, its largest moves.
• Year by year, Current Deferred Revenue stood at $26.9 million in 2018, then increased by 25.11% to $33.7 million in 2019, then advanced by 26.02% to $42.5 million in 2020, then rose by 19.74% to $50.9 million in 2021, then surged by 41.39% to $71.9 million in 2022.
• Per Business Quant data, the three most recent Current Deferred Revenue figures were $71.9 million in Q4 2022, $50.9 million in Q4 2021, and $42.5 million in Q4 2020.